Navigation Links
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a dose-escalating Phase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin (KOS-953) in combination with bortezomib (Velcade(R)), showing a high degree of antitumor activity and tolerability in patients with multiple myeloma who had previously progressed following treatment with multiple conventional therapies. The data were presented on Saturday, June 2, 2007, by Paul Richardson, M.D., Department of Hematology, Dana Farber Cancer Center, Boston, MA, in a poster titled "A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib in Relapsed Refractory Multiple Myeloma" at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Tanespimycin has significant potential as a new treatment for patients with multiple myeloma and is promising in patients with refractory disease whose need for new therapeutic options is especially important," said Dr. Richardson. "The overall profile of tanespimycin in terms of antitumor activity and tolerability, with no additive toxicity to bortezomib, is attractive and we are excited to be moving into later-stage clinical development."

"With the initiation of our TIME clinical program later this year, utilizing our new, superior injectable suspension formulation, tanespimycin will be the first Hsp90 inhibitor to enter registration trials and has the potential to be the first Hsp90 inhibitor to reach the market," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We are highly encouraged by the level of tanespimycin's activity in multiple myeloma and its tolerability and safety profile, and believe that tanespimycin has the potential to represent a breakthrough in the treatment of multiple myeloma. We appreciate th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:5/15/2008)...N.J., May 15 /- Schering-Pl...ing the science and treatment of,chronic hepatitis...a from,several clinical studies with PEGINTRON(TM)..., USP) combination therapy, as well as boceprevir,...nhibitor, will be presented at,the 39th annual Dig...
(Date:5/15/2008)...ults obtained with a newly cleared device to ident...nterest that are associated with ...Mass., May 15 /- InfraReDx, Inc. toda...n Royal Oak, Mich., have,successfully used its Lip...ergoing a cardiac catheterization. This is the fir...
(Date:5/15/2008)...15 /- CenterWatch, a publishing and,i...arch about clinical,trials, finds that investigati...ronic data capture) systems. More than 75% of resp...hat they had been trained on three or more,EDC sys...ffectiveness of,their EDC training had improved., ...
(Date:5/15/2008)...ortunity Remains for an Antiplatelet Therapy that,... the Combination of Plavix/Iscover and Aspirin...s, WALTHAM, Mass., May 15 /- Decisio...nd advisory firms for pharmaceutical and,healthcar...fient offers,improvement in patient compared to Sa...
Breaking Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Brain patterns of former anorexics reveal clues to disorders lasting impact 7345 1Brain patterns of former anorexics reveal clues to disorders lasting impact 7345 2Brain patterns of former anorexics reveal clues to disorders lasting impact 7345 3DNA methylation shown to promote development of colon tumors 1407 1DNA methylation shown to promote development of colon tumors 1407 2DNA methylation shown to promote development of colon tumors 1407 3Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II 28R 29 for Bridge to Transplantation 7343 1Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II 28R 29 for Bridge to Transplantation 7343 2Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II 28R 29 for Bridge to Transplantation 7343 3On World AIDS Day CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV AIDS 956 1On World AIDS Day CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV AIDS 956 2On World AIDS Day CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV AIDS 956 3
...pr 25, 2007 - XenoPort, Inc.,(Nasdaq: XNPT) today ... trial of XP13512 for the treatment of symptoms of...onstrated statistically,significant improvements c...ints of the trial and was well tolerated., "These ...,advance for XenoPort, its partners and, potential...
...pr 25, 2007 - DuoCort AB,today announced that resu...l release hydrocortisone tablets for adrenal insuf...gress of Endocrinology on,April 30 in Budapest. Th...of the new hydrocortisone tablets in healthy,volun...Cort 5 mg and 20 mg,hydrocortisone dual-release ta...
Other Medicine Technology:XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 2XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 3XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 4XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 5DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology 2
(Date:5/16/2008)...rs More than 500 Workers, WASHINGTON, May 16 /PRN...d emergency medical technicians in the Greater Por...ratified their first-ever contract as,Teamsters., ... now covered by a,strong contract that gives them ...id Teamsters General President Jim Hoffa., The wo...
(Date:5/16/2008)...ic disease sufferers gain benefit from calcitriol,...Day News) -- Taking activated vitamin D may cut th... chronic kidney disease by about one quarter, a ne... more than 1,400 patients, those being treated wit... had their overall risk of death lowered by 26 per...
(Date:5/16/2008)...la., May 16 /PRNewswire-USNewswire/- "Huh, what di...mericans, particularly our,children. More than 30 ...e,significant hearing loss and the numbers are gro... school age children have some form of hearing,los...l and economic problem,is what led Kathlyn Maguire...
(Date:5/16/2008)...ast Scheduled for May 19 at 10:15 a.m. Eastern Tim...ponse Biomedical,Corporation (TSX: RBM, OTCBB: RPB...tive Officer, is scheduled to present at the Rodma...e on Monday May 19th at 10:15 a.m.,EDT., A live w...he Company,s,Web site at, http://www.responsebio.c...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
...ng to surgeons, they use sound waves to pulverize ...termine if less powerful ultrasound can improve th...re blood flow to the brain.// Dr. Andrei Alexandro...intracranial ultrasound to track the efficacy of t...
...rax and other biological weapons continue to be wo...methyl bromide is more effective and cheaper// tha...al spores from buildings. Tests indicate that the ...ntrol insect pests in buildings, grain elevators a...
...ng to researchers, a drug commonly used for short-...talized patients may cause dangerously low blood p... suggest that the drug, milrinone, should be reser... other medication, said Dr. Mihai Gheorghiade of N...
...anti-smoking drug be injurious to health? Pharma g...ts smoking cessation drug, Zyban, has risen in def...f unproven reports in the UK, linking the drug to ...ted to be the world’s most successful smoking cess...
Other Medicine News:Health News:Ultrasound helps stroke treatment 2Health News:Heart Drug has grave side effects 2
The Quinton Q-Stress Cardiac Stress Monitor combines Quinton algorithms, unique baseline wander and muscle artifact filters, and 8000 samples per second to provide the highest ECG fidelity in the ind
...gh in non-invasive cardiac diagnosis, the fully fe...only stress test system that measures T-wave alter...ck provides a quality control facility, this combi...filters the signal ensuring outstanding and noise-...
...90E Automatic Chart Projector makes refracting eas...ts you program up to 33 charts in any order you wi...kened room simply by pressing one button each time...the CP-690E's programmable random access gives you...
The Urchin heart positioner provides excellent access to target coronaries while minimizing hemodynamic instability
Medicine Products: